Search Press releases Keywords From To 24 May 2022 Transparency notification FMR LLC Read More 23 May 2022 First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022 Read More 23 May 2022 UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022 Read More 20 May 2022 Disposal of own shares Read More 18 May 2022 Transparency notification Wellington Read More 13 May 2022 Disposal of own shares Read More Pagination First page Previous page Previous … Page 19 Page 20 Page 21 Page 22 Current page 23 Page 24 Page 25 Page 26 Page 27 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
